Quick answer: Journavx (suzetrigine) is FDA-approved for one thing: moderate-to-severe acute (short-term) pain in adults, based on trials in post-surgical patients. It is not currently approved for chronic nerve pain conditions like diabetic peripheral neuropathy or sciatica. Research into those uses is underway, but results aren’t in yet — and until the label changes, that distinction matters for anyone trying to make sense of the headlines.
Why the Acute-vs-Chronic Distinction Matters
Journavx was approved by the FDA on January 30, 2025 as the first new class of prescription pain medicine in more than 20 years — a non-opioid option that blocks pain signals at a specific sodium channel (NaV1.8) found in peripheral nerves, rather than acting on the brain the way opioids do. That’s a meaningful development for people recovering from surgery or injury.
But “a new way of blocking pain signals” and “approved for every kind of pain” are not the same statement. The approval is scoped tightly to short-term, acute pain. If you or someone you’re supporting is dealing with chronic nerve pain — the kind that comes with diabetic peripheral neuropathy, sciatica, or lumbosacral radiculopathy — the current label doesn’t cover that use. It’s worth understanding exactly where that line sits before drawing conclusions from the coverage.
Does the Acute-Pain Approval Cover Neuropathy?
No. The FDA’s approval of Journavx is specifically for management of moderate-to-severe acute pain in adults. The two pivotal trials that supported approval studied people recovering from bunionectomy (bunion removal) and abdominoplasty (tummy tuck) surgery, measuring pain reduction over a 48-hour window against placebo. Both trials met that primary goal. Both trials also compared suzetrigine to a combination opioid (hydrocodone/acetaminophen) as a secondary measure, and did not meet that secondary comparison — a detail worth knowing if you see suzetrigine described simply as “as good as” that combination, since the trial data don’t fully support that framing.
Diabetic peripheral neuropathy, sciatica, and lumbosacral radiculopathy are chronic nerve pain conditions, with different underlying biology and a different treatment timeline than post-surgical pain. The approved label does not extend to them. Using Journavx for chronic neuropathic pain today would be off-label — outside what the FDA has specifically reviewed and authorized.
The mechanism (blocking a signaling channel concentrated in peripheral nerves) is a reasonable scientific basis for asking whether it might also help chronic nerve pain. That’s a hypothesis researchers are actively testing — not a settled answer.
What Studies Would Support a New Use?
The manufacturer, Vertex Pharmaceuticals, has an active research program in peripheral neuropathic pain:
- Phase 2, diabetic peripheral neuropathy (NCT05660538): completed, with 194 participants comparing suzetrigine at three doses against pregabalin (a commonly used nerve-pain medication) and placebo over 12 weeks. Vertex reported that suzetrigine produced statistically significant, clinically meaningful reductions in pain versus placebo, measured on the Numeric Pain Rating Scale.
- Phase 3, diabetic peripheral neuropathy (NCT06628908): a randomized, double-blind study comparing suzetrigine to pregabalin and placebo in about 1,100 adults with diabetes-related nerve pain. Status: actively recruiting, with an estimated primary completion date of May 2027.
- Long-term extension study (NCT06696443): following participants who complete the Phase 3 program, tracking long-term safety and effectiveness. Status: active, no longer recruiting.
- Vertex has also reported positive Phase 2 results in painful lumbosacral radiculopathy (sciatica-type nerve pain), though detailed results have not been fully published.
Public reporting indicates Vertex’s confirmatory Phase 3 program for diabetic peripheral neuropathy is built around two parallel 12-week placebo-controlled studies rather than one. We’ve verified the first (NCT06628908) directly; we were not able to independently confirm the registry number for the second before publishing this piece, so we’re not citing one we can’t verify — see the note to our editorial team below.
In practical terms: a chronic-pain approval, if it happens, depends on these ongoing Phase 3 trials reporting positive results, followed by FDA review. That timeline is measured in years — the lead trial’s estimated primary completion date is mid-2027.
Where Can I Verify the Current Label?
Because this is a prescription medication whose approved uses could expand as trial data comes in, it’s worth checking primary sources directly rather than relying on any summary, including this one:
- The FDA’s Drug Safety and Availability page for official approval and safety communications.
- The National Institute of Neurological Disorders and Stroke’s overview of peripheral neuropathy for background on the condition itself, independent of any specific drug.
- ClinicalTrials.gov listings for suzetrigine (search NCT06628908) for current recruiting status and any posted results as the trial progresses.
A prescribing clinician has access to the complete, current prescribing information, which is the right source for an actual treatment decision.
A Note on What We Can’t Tell You From Here
We’re not able to look at a description of symptoms and tell you whether what you’re experiencing is acute or chronic nerve pain, or whether a specific medication is appropriate for you — that calls for an in-person clinical evaluation. A few things are worth flagging to a clinician promptly rather than researching further on your own: new or worsening nerve symptoms (numbness, weakness, or pain that’s spreading or intensifying), any sign of infection or recent trauma near the affected area, or signs of a circulation problem (coldness, color change, or swelling in a limb). None of this is a reason to start, stop, or change any medication on your own — that decision belongs with the clinician who knows your full medical picture.
A Simple Tool: Keeping a Pain-and-Function Journal
Whether your pain turns out to be acute or chronic, a short daily log gives your care team something concrete to work with — more useful than trying to recall weeks of symptoms from memory in a single appointment. Track:
- Location — where exactly the pain is, and whether it’s one-sided or bilateral (bilateral lower-limb pain is a defining feature of diabetic peripheral neuropathy specifically).
- Sensation — sharp, burning, tingling, numb, electric-shock-like, or aching. The type of sensation helps distinguish nerve pain from muscle or joint pain.
- Onset — did it start suddenly (more typical of an acute cause) or build gradually over weeks or months (more typical of chronic neuropathic pain)?
- Activity limits — what you can no longer do, or do only with difficulty, because of the pain.
- Red-flag symptoms — swelling, fever, a visible injury, or skin changes (especially relevant if you have diabetes) — bring these to a clinician promptly rather than waiting for a scheduled visit.
- Your one question — write down the single thing you most want answered, so it doesn’t get lost in a short appointment.
Useful Next Steps
A few grounded next steps if you’re trying to sort out acute versus chronic nerve pain, or whether a newer non-opioid option might eventually apply to your situation:
- Bring your pain-and-function journal to your next appointment so your clinician has specifics to work from.
- Ask directly whether your pain pattern is classified as acute or chronic, since that distinction affects which treatments are currently available to you.
- If you’re living with diabetic peripheral neuropathy and interested in emerging research, ask your clinician whether a clinical trial might be appropriate — that’s the legitimate current path to access, rather than seeking an approved acute-pain medication off-label.
- For more on how chronic nerve pain is evaluated and managed, see our Nerve Pain coverage.
Keep reading